

RECEIVED
CENTRAL FAX CENTER

APR 25 2006



GlaxoSmithKline

FAX

To Attn: Art Unit 3754
.....
Company USPTO
.....
Fax 571-273-8300
.....
From Valerie L. Phillips
.....
Tel 919-483-8223 Fax 919-483-5730
.....
E-mail Vlp47157@gsk.com
.....
Date April 25, 2006 Pages including cover 7
.....
Subject Request for Corrected Filing Receipt
.....

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Serial No.: 10/561,375
Filing Date: 12/16/2005
Applicant: Anderson et al.
Title: A Dispenser


BEST AVAILABLE COPY

Attached:
Certificate of transmission via facsimile
Request for Corrected Filing Receipt
Copy of Official Filing Receipt

Thank you,
Valerie Phillips

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Request for Corrected Filing Receipt is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 571-273-8300) on April 25, 2006.


Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

PB60389USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

APR 25 2006

In re Application of: Anderson et al.
Serial No.: 10/561,375
Filed: December 16, 2005
For: A Dispenser

Art Unit: 3754
Examiner:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.
2. There is an error with respect to the following data, which is:
- 3.

☒ Incorrectly entered

and/or

☐ omitted.


Error in

1. ☒ Applt's name: Gregor John McLennan Anderson
2. ☐ Applt's address:
3. ☒ Title: Dispenser
4. ☐ Filing date:
5. ☐ Serial Number
6. ☐ Foreign Applications
7. ☐ Other -:

Correct data

1. Gregor John McLennan Anderson
- 2.
3. A Dispenser
- 4.
- 5.
- 6.
- 7.

4. Charge Account 07-1392 for any fees which may be due.


J. Scott Young

Registration No.: 45,582

Date:
GlaxoSmithKline
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Phone: 919-483-8222
Fax: 919-483-7988

APR. 25. 2006 3:56PM

GW GLOBAL R&D IS

RECEIVED
CENTRAL FAX CENTER

NO. 0900 Page 3 of 3



UNITED STATES PATENT AND TRADEMARK OFFICE

APR 25 2006

COPIED TO THE UK
dpm/jor/154/val
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE RECD	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/561,375	12/16/2005	3754	1350	PB60389 USW	18	29	1

CONFIRMATION NO. 5331

23347

GLAXOSMITHKLINE
CORPORATE INTELLECTUAL PROPERTY, MAI B475
FIVE MOORE DR., PO BOX 13398
RESEARCH TRIANGLE PARK, NC 27709-3398

FILING RECEIPT

 OC000000018333091

Date Mailed: 04/05/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Gregor John McLellan Anderson, Hertfordshire, UNITED KINGDOM;
James Terence Collins, Cambridgeshire, UNITED KINGDOM;
Ralph George Lambie, Cambridgeshire, UNITED KINGDOM;
Allen John Pearson, Cambridgeshire, UNITED KINGDOM;
Tom Snow, Cambridgeshire, UNITED KINGDOM;
Paul John Turner, Cambridgeshire, UNITED KINGDOM;

Assignment For Published Patent Application

GLAXO GROUP LIMITED

BEST AVAILABLE COPY

Power of Attorney: The patent practitioners associated with Customer Number 23347.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP04/07808 07/09/2004


Foreign Applications

UNITED KINGDOM 0316348.2 07/11/2003

If Required, Foreign Filing License Granted: 03/21/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/561,375**

Projected Publication Date: 06/29/2006



Non-Publication Request: No

Early Publication Request: No

Title

Dispenser

Preliminary Class

222

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but **does not** result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where

the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

BEST AVAILABLE COPY

BEST AVAILABLE COPY**UNITED STATES PATENT AND TRADEMARK OFFICE**

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/561,375	FIRST NAMED APPLICANT Gregor John McLenan Anderson	ATTY. DOCKET NO. PB60389 USW
INTERNATIONAL APPLICATION NO. PCT/EP04/07808		
LA. FILING DATE 07/09/2004	PRIORITY DATE 07/11/2003	

23347
 GLAXOSMITHKLINE
 CORPORATE INTELLECTUAL PROPERTY, MAI B475
 FIVE MOORE DR., PO BOX 13398
 RESEARCH TRIANGLE PARK, NC 27709-3398

CONFIRMATION NO. 5331**371 ACCEPTANCE LETTER**

OC000000018333092

Date Mailed: 04/05/2006

NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.495

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is **ACCEPTED** for national patentability examination in the United States Patent and Trademark Office.


The United States Application Number assigned to the application is shown above and the relevant dates are:

<u>12/16/2005</u>	<u>12/16/2005</u>
DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS	DATE OF COMPLETION OF ALL 35 U.S.C. 371 REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. **THE DATE APPEARING ON THE FILING RECEIPT AS THE " FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371 (c)(1), (c)(2) and (c)(4) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE.** The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363). Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

The following items have been received:

- Copy of the International Application filed on 12/16/2005
- Copy of the International Search Report filed on 12/16/2005
- Preliminary Amendments filed on 12/16/2005
- Information Disclosure Statements filed on 12/16/2005
- Oath or Declaration filed on 12/16/2005
- Request for Immediate Examination filed on 12/16/2005
- U.S. Basic National Fees filed on 12/16/2005
- Assignment filed on 12/16/2005
- Priority Documents filed on 12/16/2005
- Power of Attorney filed on 12/16/2005



APR. 25. 2006 3:58PM

GW GLOBAL R&D IS

NO. 0900 Page 7 of 2

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

SHELBY J VIGIL

Telephone: (703) 308-9140 EXT 224

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/903 (371 Acceptance Notice)

BEST AVAILABLE COPY

APR 25, 2006 3:58PM

GW GLOBAL R&D IS

NO. 0900 P. 8

File Copy



Pricilla L Jones/CORP
20-Apr-2006 11:29

GlaxoSmithKline - Corporate Intellectual Property
MAI.B471B RTP 919-483-1304
To Jason N Rice/CORP/GSK@GSK
cc Scott S Young/CORP/GSK@GSK, Denise A
Gerrard/CORP/GSK@GSK

bcc
Subject INFORMATION ONLY - PB60389-C USw

Jason,

Information only.

Regards,

Pricilla L. Jones
Patent Paralegal
Direct Line: 919-483-1304
Fax: 919-483-7988
E-mail: Pricilla. L. Jones@gsk.com

BEST AVAILABLE COPY

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.



PB60389USw.pdf